TP53 and lung carcinoma: Morro et al. developed the CCL660 system encapsulated miR-660, which targets MDM2 in cationic Lipid-NPs.581 Systemic administration of CCL60 in mice models of lung cancer resulted in an upregulation of miRNA levels within tumors and an inhibition of tumor growth in both P53 wild-type and mutation-type tumors.